2Meisner Franz, Walcher Daniel, Gizard Florence, et al. Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients: Data From a Randomized Placebo-Controlled Trial[ J]. Arteriosclerosis thrombosis and vascular biology, 2006, 26(4) : 845 - 850.
3Hetzel Jtirgen, Balletshofer Bemd, Rittig Kihan, et al. RapidEffects of Rosiglitazone Treatment on Endothelial Function and Inflammatory Biomarkers [J]. Arteriosclerosis thrombosis and vascular biology, 2005,25 (9) : 1804 - 1809.
4Matsumoto T, Noguchi E, Kobayashi T, et al. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in theimpaired endothelium-dependent relaxation seen in aortas from diabetic rats[ J]. Free Radic Biol Med, 2007,42 (7) : 993 - 1007.
5van Wijk JP, Cabezas MC, Coll B, et al. Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetes[ J]. Atherosclerosis, 2006,186( 1 ): 152 - 159.
6Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR[ gamma]-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease[J]. Arterioscler Thromb Vasc Biol,2003,23 ( 2 ) : 283.
7Marfella R, D' Amico M, Esposito K, et al. The ubiquitin-pmteasome system and inflammatory activity in diabetic atherosclerotie plaques : effects of rosiglitazone treatment [J ]. Diabetes, 2006,55 ( 3 ) : 622 - 632.
9Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to itsantidiabetic effect [ J ]. Diabetes Care,2003,26 ( 9 ) : 2493 - 2499.
3Wong M, Edelstein J, Wollman J, et al. Ultrasonic-pathological comparison of the human arterial wall: verification of intima-media thickness [ J ]. arterioscler Thromb, 1993, 13: 482 - 486.
4Norhammar,et al. Glucose metabolism in patients acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study[ J]. Lancet, 2002:359:2140 - 2144.
6Hsueh WA, Law RE. Insulin signaling in the arterial wall[J]. Am J Cardiol, 1999, 84:21.
7The DECODE study group, European Diabetes Epidemiology Group.Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria [ J ]. Lancet, 1999, 354 :617 -621.
